ESR2 and renal cell carcinoma: found that targeting ERβ/circDGKD by downregulating VE-cadherin reduced RCC growth and proliferation and significantly weakened the VM formation, which is envisaged to enhance the efficacy of Sunitinib providing a new combinational therapy strategy to prevent RCC progression (74).